theory clinical_1_9
imports Main

begin

typedecl entity
typedecl event

consts
  Olaparib :: "entity ⇒ bool"
  Rucaparib :: "entity ⇒ bool"
  PARP1Inhibitor :: "entity ⇒ bool"
  LicensedForUseIn :: "entity ⇒ entity ⇒ bool"
  ProstateCancerPatient :: "entity ⇒ bool"
  TreatmentOption :: "entity ⇒ bool"
  Patient :: "entity ⇒ bool"
  LossOfBRCA2 :: "entity ⇒ bool"
  MechanismOfAction :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  SyntheticLethality :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Cell :: "entity ⇒ bool"
  Rely :: "entity ⇒ bool"
  Mechanism :: "event ⇒ bool"
  Repair :: "event ⇒ bool"
  Damage :: "event ⇒ bool"
  DNA :: "event ⇒ bool"
  Make :: "event ⇒ bool"
  DistinctTreatmentOption :: "entity ⇒ bool"
  Drug :: "entity ⇒ bool"
  Different :: "entity ⇒ entity ⇒ bool"
  UniqueProperties :: "entity ⇒ bool"
  Share :: "entity ⇒ bool"
  Similar :: "entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"
  Has :: "event ⇒ bool"
  ViableOption :: "entity ⇒ bool"
  DistinctOption :: "entity ⇒ bool"
  ForTreatment :: "event ⇒ bool"

(* Explanation 1: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_1: "∀x y z. Olaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ ProstateCancerPatient y ∧ TreatmentOption x ∧ Patient z ∧ LossOfBRCA2 z ∧ MechanismOfAction x"

(* Explanation 2: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a potential treatment option for any patient with loss of BRCA2 due to its mechanism of action. *)
axiomatization where
  explanation_2: "∀x y z. Rucaparib x ∧ PARP1Inhibitor x ∧ LicensedForUseIn x y ∧ ProstateCancerPatient y ∧ TreatmentOption x ∧ Patient z ∧ LossOfBRCA2 z ∧ MechanismOfAction x"

(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality, which causes cells to rely on a singular mechanism to repair cumulative damage to DNA, making Olaparib and Rucaparib viable treatment options. *)
axiomatization where
  explanation_3: "∀x y z e1 e2 e3 e4. Patient x ∧ LossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ Cause e2 ∧ Agent e2 z ∧ Cell e3 ∧ Rely e3 ∧ Mechanism e4 ∧ Repair e4 ∧ Damage e4 ∧ DNA e4 ∧ Make e4 ∧ Agent e4 e3 ∧ TreatmentOption e3"

(* Explanation 4: The patient in question has a loss of BRCA2, which makes both Olaparib and Rucaparib viable treatment options for them due to their mechanism of action. *)
axiomatization where
  explanation_4: "∃x y z e1 e2. Patient x ∧ LossOfBRCA2 y ∧ Has e1 ∧ Agent e1 x ∧ Make e2 ∧ Agent e2 y ∧ TreatmentOption z ∧ For z x ∧ MechanismOfAction z"

(* Explanation 5: Olaparib and Rucaparib are distinct treatment options because they are different drugs with unique properties, even though they share a similar mechanism of action. *)
axiomatization where
  explanation_5: "∀x y z. Olaparib x ∧ Rucaparib y ∧ DistinctTreatmentOption x ∧ DistinctTreatmentOption y ∧ Drug x ∧ Drug y ∧ Different x y ∧ UniqueProperties x ∧ UniqueProperties y ∧ Share z ∧ MechanismOfAction z ∧ Similar z"

(* Explanation 6: Olaparib and Rucaparib are distinct treatment options for patients with loss of BRCA2 because they are different drugs with unique properties, and both are licensed for use in prostate cancer patients, making them viable and distinct options for treatment. *)
axiomatization where
  explanation_6: "∀x y z e1 e2. Olaparib x ∧ Rucaparib y ∧ Patient z ∧ LossOfBRCA2 z ∧ DistinctTreatmentOption x ∧ DistinctTreatmentOption y ∧ For x z ∧ For y z ∧ Drug x ∧ Drug y ∧ Different x y ∧ UniqueProperties x ∧ UniqueProperties y ∧ LicensedForUseIn x z ∧ LicensedForUseIn y z ∧ ProstateCancerPatient z ∧ Make e1 ∧ Agent e1 x ∧ ViableOption x ∧ ViableOption y ∧ DistinctOption x ∧ DistinctOption y ∧ ForTreatment e2"

theorem hypothesis:
  assumes asm: "Patient z"
  (* Hypothesis: There are two potential treatment options for this patient. *)
  shows "∃x y. TreatmentOption x ∧ TreatmentOption y ∧ Patient z ∧ For x z ∧ For y z"
proof -
  (* From the premise, we know that z is a patient. *)
  from asm have "Patient z" by simp
  (* Explanation 4 states that the patient in question has a loss of BRCA2, making both Olaparib and Rucaparib viable treatment options. *)
  (* This implies that there exist x and y such that TreatmentOption x and TreatmentOption y hold for the patient z. *)
  from explanation_4 have "∃x y. TreatmentOption x ∧ TreatmentOption y ∧ For x z ∧ For y z" sledgehammer
  then show ?thesis <ATP>
qed

end
